After controlling the confounding effects by malignancy grade and IDH mutations on patients' survival, we still observed a significant association between high expression of gp96 and unfavorable clinical outcomes (Figures 2(d)–2(i)), reflecting that gp96's high expression has an independent and negative impact on outcomes of glioma patients. This evidence concerns the gene HSP90B1 and glioma.